Ginkgo Bioworks Holdings, Inc. is a biotechnology company that provides biological R&D services and biosecurity solutions. The company operates in two primary business segments: cell engineering and biosecurity. In cell engineering, Ginkgo offers tools and services for the discovery, optimization, and manufacturing of biotechnology products, including DNA and RNA sequences for vaccines, gene therapies, and industrial bioproducts. Its platform utilizes an Autonomous Lab built from Reconfigurable Automation Cart (RAC) systems to generate data for generative AI and machine learning tools, alongside reusable data assets such as host cells and metagenomic libraries. Customers in this segment include entities in medicine, agriculture, industrial biotechnology, and government sectors. In the biosecurity segment, Ginkgo provides services to identify, monitor, and mitigate biological threats, primarily serving government customers. Key offerings in this area include Canopy, a biomonitoring program that generates genomic data from strategic nodes like airports, and Horizon, a digital surveillance and analytics platform for detecting biothreats worldwide. The company was co-founded in 2008.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ginkgo.bio
Sector Healthcare IR page investors.ginkgobioworks.com/overview/default.aspx
Tags
synthetic biology, autonomous labs, biosecurity, biomonitoring, genomic data, cell engineering, industrial biotechnology, vaccine development, gene therapy, machine learning, Canopy, Horizon, Reconfigurable Automation Cart, RAC, Autonomous Lab
Press page —

Metrics

Valuation  
Market cap $ 654.193M
Market cap (USD) $ 654.193M
P/E -1.80
PEG —
P/BV 1.67
P/S 6.49
P/OCF -3.92
P/FCF -3.77
Dividend yield —
Turnover / mcap —
Returns  
ROE -51.1%
ROI -41.2%
ROIC -31.2%
Profit margin -183.8%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 170.155M 227.043M 251.455M 477.706M 313.837M 76.657M
Net profit -312.763M -547.029M -892.869M -2.105B -1.83B -126.609M
Free cash flow -178.724M -382.126M -336.301M -304.469M -310.339M -193.651M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 8.31 9.82 1.69 1.69 8.31 2.4
Price performance 12m -0.15 4.81 0 -0.8 2.46 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 16.7M 132M 80.9M 17.2M 21.9M 24M
↳ YoY growth +688.0% -38.5% -78.8% +27.4% +9.9%
↳ 5y CAGR +7.6%
Lease liabilities (USD) — — 16.5M 22.3M 443M 242M 468M 440M
Cash and deposits (USD) 207M 499M 0.00 1.55B 1.32B 944M 562M 167M
Intangible assets (USD) — — 3.29M 21.6M 111M 82.7M 72.5M 56.9M
Right-of-use assets (USD) — — — 0.00 401M 207M 394M 361M
Cash flow detail
Operating cash flow (USD) — -44.7M -136M -254M -252M -296M -320M -171M
Purchases of property, plant and equipment (USD) — -22.2M -57.8M -56.5M -52.3M -40.8M -62.5M -7.67M
Change in receivables (cash effect) (USD) — -1.84M -14.2M -114M 55M 50.1M -4.73M -1.47M
Change in inventories (cash effect) (USD) — — -2.74M -626,000 164,000 — — —
Change in payables (cash effect) (USD) — 664,000 7.02M -2.25M -10.8M -1.18M 4.77M -2.99M
Share buybacks (cash effect) (USD) — -408,000 — — — — — —
Interest paid (cash effect) (USD) — -2.35M -2.57M -2.37M -92,000 -83,000 -32,000 -4,000
Income taxes paid (cash effect) (USD) — -31,000 0.00 -9.46M -981,000 -23,000 0.00 -192,000
Share-based compensation (USD) — 771,000 476,000 1.61B 1.93B 230M 112M 81.5M
Operating cash flow before change in receivables (USD) — -42.8M -122M -140M -307M -346M -315M -170M
Free cash flow (OCF - PPE - intangibles) (USD) — -66.9M -194M -310M -304M -336M -382M -179M
Income detail
Research and development expense (USD) — 96.3M 160M 1.15B 1.05B 581M 424M 244M
↳ 5y CAGR +34.5% +8.8%
Total comprehensive income (USD) — -120M -127M -1.84B -2.11B -889M -550M -309M
Comprehensive income to owners (USD) — -120M -127M -1.84B -2.11B -889M -550M -309M
Reported Mar 29, 2022 Mar 29, 2022 Mar 13, 2023 Mar 13, 2023 Mar 13, 2023 Feb 29, 2024 Feb 25, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

Download(opens in new window)

Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab

BOSTON--(BUSINESS WIRE)-- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com .

Third Quarter 2026 Financial Results

  • Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year period, a decrease of 6%. Revenue increased from $20 million in the second quarter of 2026.
  • Third quarter 2026 GAAP net loss from continuing operations of ($41) million, compared to ($73) million in the comparable prior year period.
  • Third quarter 2026 Adjusted EBITDA of ($22) million, improved from ($53) million in the comparable prior year period.
  • Cash, cash equivalents and marketable securities balance as of September 30, 2026 of $285 million.
  • Third quarter 2026 cash burn of $27 million.

"Ginkgo now has two core offerings built on one autonomous lab platform," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research."

Recent Business Highlights & Strategic Positioning

  • Two prevailing offerings built on one autonomous lab platform.
    • Autonomous Labs Equipment: we sell RAC + Catalyst systems to pharma, national labs, universities and the U.S. government, including Novo, Pacific Northwest National Laboratory, the NSF and ARPA-H.
    • Cloud Lab Services: we run experiments in Nebula, the world’s largest autonomous lab with more than 100 reconfigurable automation carts (RACs), delivering onshore ADME, DRUG-seq and antibody data for pharma, and AI training data for frontier labs and techbio companies.
    • The U.S. government is making autonomous labs national infrastructure through the Genesis Mission, the NSF’s ~$400 million Programmable Cloud Laboratories (PCL) Test Bed, and the $1.5 billion X-Labs initiative, where Ginkgo is providing access to Nebula, as announced by the White House Office of Science and Technology Policy on October 8.
  • Autonomous Labs are growing with new deals.
    • Novo: an autonomous lab sale to a top-tier pharma company at Novo’s new Waltham, Massachusetts R&D site.
    • ARPA-H GIVE: subcontract worth up to $17.5 million to put RACs and Catalyst into RNA-medicine manufacturing for the first time.
    • Building on momentum from previously-announced Caltech, University of Maryland and Northwestern commissions of Ginkgo-built labs under the NSF’s PCL Test Bed, and MIT Media Lab’s construction of a RAC-based cloud lab.
  • Cloud Lab is growing with new pharma logos and AI data generation.
    • Our ADME-One service is orders of magnitude cheaper than WuXi, with work done in Boston; 22 ADME customers signed in Q3 and 20 were first-time Ginkgo customers.
    • Takeda, Argenx, Lundbeck and AbbVie founded our Antibody Developability Consortium; GSK, Novartis and Biogen also signed new work.
    • Frontier AI labs like OpenAI are using our Cloud Lab for AI data generation.

Full Year 2026 Outlook

  • Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.

Conference Call Details

Ginkgo will host a videoconference today, Thursday, November 5, beginning at 4:30 p.m. ET. The presentation will include an overview of the third quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)
+1 301 715 8592 (Washington DC - ET)
+1 305 224 1968 (Miami - ET)
+1 689 278 1000 (Orlando - ET)
+1 312 626 6799 (Chicago - CT)
+1 507 473 4847 (Minnesota - CT)
+1 346 248 7799 (Houston - CT)
+1 719 359 4580 (Colorado - MT)
+1 408 638 0968 (San Jose - PT)

Webinar ID: 952 0773 4867

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

About Ginkgo Bioworks

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers’ needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as Novo and OpenAI), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations concerning increased government investment in and contracting for autonomous laboratory infrastructure, expectations regarding the development, performance and future enhancements of our platform and new product and service introductions, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release, and (xix) the risks relating to significant disruptions to our and our service providers’ information technology systems or data security incidents. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, Ginkgo’s quarterly report on Form 10-Q, once filed, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Use of Non-GAAP Financial Measures

Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation in the Appendix of this quarter’s earnings presentation for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.

Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share data)

As of September 30, 2026 As of December 31, 2025
Assets
Current assets:
Cash and cash equivalents $ 84,504 $ 167,202
Marketable securities 200,857 255,418
Accounts receivable, net 11,485 24,026
Accounts receivable - related parties — 229
Prepaid expenses and other current assets (includes $4,208 and zero from related parties) 13,995 24,963
Total current assets 310,841 471,838
Restricted cash and marketable securities, non-current 84,237 38,138
Property, plant and equipment, net 152,347 167,371
Operating lease right-of-use assets 341,494 360,918
Investments 8,949 15,066
Equity method investments 5,607 —
Intangible assets, net 39,731 53,482
Other non-current assets 1,246 9,029
Assets held for sale — 3,854
Total assets $ 944,452 $ 1,119,696
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 7,181 $ 10,566
Deferred revenue (includes $98 and $98 from related parties) 6,388 18,946
Accrued expenses and other current liabilities (includes $5,564 and zero from related parties) 52,280 66,458
Total current liabilities 65,849 95,970
Non-current liabilities:
Deferred revenue, net of current portion (includes $64,810 and $64,787 from related parties) 71,977 75,182
Operating lease liabilities, non-current 397,198 417,078
Other non-current liabilities 16,791 22,876
Total liabilities 551,815 611,106
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued — —
Common stock, $0.0001 par value (Note 8) 6 6
Additional paid-in capital 6,713,117 6,657,053
Accumulated deficit (6,320,601 ) (6,150,320 )
Accumulated other comprehensive income 115 1,851
Total stockholders’ equity 392,637 508,590
Total liabilities and stockholders’ equity $ 944,452 $ 1,119,696

Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share data)

Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenue(1) $ 27,711 $ 29,380 $ 67,341 $ 106,744
Costs and operating expenses:
Cost of other revenue 1,806 4,625 6,623 14,095
Research and development 40,945 69,353 137,075 193,646
General and administrative 28,593 36,986 97,198 111,690
Restructuring charges — 721 — 8,753
Total operating expenses 71,344 111,685 240,896 328,184
Loss from operations (43,633 ) (82,305 ) (173,555 ) (221,440 )
Other income (expense):
Interest income, net 3,060 5,742 9,888 17,906
Loss on equity method investment (2,008 ) — (6,681 ) —
Gain (loss) on investments (287 ) 3,684 486 (238 )
Other income (expense), net 1,613 (474 ) (4,725 ) (6,280 )
Total other income (expense) 2,378 8,952 (1,032 ) 11,388
Loss from continuing operations before income taxes (41,255 ) (73,353 ) (174,587 ) (210,052 )
Income tax (benefit) expense (271 ) 1 (223 ) (194 )
Net loss from continuing operations $ (40,984 ) $ (73,354 ) $ (174,364 ) $ (209,858 )
Net income (loss) from discontinued operations, net of tax — (7,401 ) 4,083 (22,154 )
Net loss $ (40,984 ) $ (80,755 ) $ (170,281 ) $ (232,012 )
Net income (loss) per share:
From continuing operations $ (0.64 ) $ (1.32 ) $ (2.82 ) $ (3.82 )
From discontinued operations — (0.13 ) 0.07 (0.40 )
Total net loss per share $ (0.64 ) $ (1.45 ) $ (2.75 ) $ (4.22 )
Weighted average common shares outstanding: 63,966,054 55,633,718 61,890,748 54,916,539
Comprehensive loss:
Net loss (40,984 ) (80,755 ) (170,281 ) (232,012 )
Other comprehensive (loss) income:
Foreign currency translation adjustment (515 ) 27 (1,128 ) 3,462
Unrealized (loss) gain on available-for-sale securities (320 ) 316 (608 ) 340
Total other comprehensive (loss) income (835 ) 343 (1,736 ) 3,802
Comprehensive loss $ (41,819 ) $ (80,412 ) $ (172,017 ) $ (228,210 )

(1) Includes related party revenue of zero for the three months ended September 30, 2026 and 2025, and zero and $8,518 for the nine months ended September 30, 2026 and 2025, respectively.

Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)

Nine Months Ended September 30,
2026 2025
Cash flows from operating activities:
Net loss $ (170,281 ) $ (232,012 )
Net income (loss) from discontinued operations, net of tax 4,083 (22,154 )
Net loss from continuing operations (174,364 ) (209,858 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 37,152 43,695
Stock-based compensation 31,117 51,226
(Gain) loss on investments (486 ) 275
Loss on equity method investment 6,681 —
Change in fair value of notes receivable 6,759 5,685
Change in fair value of contingent consideration — (4,232 )
Non-cash lease expense 19,423 22,449
Accretion of discount on marketable securities 89 (2,502 )
Other non-cash activity (1,057 ) 1,611
Changes in operating assets and liabilities:
Accounts receivable 4,968 1,448
Prepaid expenses and other current assets 3,211 (775 )
Operating lease right-of-use assets — 3,814
Other non-current assets 297 (38 )
Accounts payable, accrued expenses and other current liabilities (14,312 ) 17,432
Deferred revenue, current and non-current zero and $(7,958) from related parties (14,443 ) (27,448 )
Operating lease liabilities, current and non-current (16,713 ) (18,793 )
Other non-current liabilities (5,276 ) 4,459
Net cash used in operating activities - continuing operations (116,954 ) (111,552 )
Net cash used in operating activities - discontinued operations (2,353 ) (11,829 )
Net cash used in operating activities (119,307 ) (123,381 )
Cash flows from investing activities:
Purchases of marketable debt securities (216,800 ) (401,838 )
Maturities of marketable debt securities 231,108 73,599
Purchases of property and equipment (6,552 ) (7,660 )
Proceeds from sale of investment 1,850 —
Other 512 511
Net cash provided by (used in) investing activities 10,118 (335,388 )
Cash flows from financing activities:
Proceeds from ATM offering 23,795 10,317
Payment of issuance costs related to ATM offering (802 ) (355 )
Principal payments on finance leases (19 ) (329 )
Net cash provided by financing activities 22,974 9,633
Effect of foreign exchange rates on cash and cash equivalents (80 ) 353
Net decrease in cash, cash equivalents and restricted cash (86,295 ) (448,783 )
Cash and cash equivalents, beginning of period 167,202 561,572
Restricted cash, beginning of period 45,169 44,171
Cash, cash equivalents and restricted cash, beginning of period 212,371 605,743
Cash and cash equivalents, end of period 84,504 111,065
Restricted cash, end of period 41,572 45,895
Cash, cash equivalents and restricted cash, end of period $ 126,076 $ 156,960

The following table presents summary results of the Company’s reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):

Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Cell Engineering
Revenue $ 27,711 $ 29,380 $ 67,341 $ 106,744
Costs and operating expenses:
Cost of other revenue(1) 1,608 2,994 5,752 9,980
Research and development(1) 26,670 50,954 87,208 130,689
General and administrative(1) 9,317 13,758 33,148 49,397
Stock-based compensation(2) 7,767 15,249 32,512 51,732
Depreciation and amortization 12,038 13,624 37,152 43,695
Restructuring charges(3) — 721 — 8,753
Carrying cost of excess space (net of sublease income)(4) 13,989 14,328 44,063 38,416
Merger, acquisition and divestiture related expense (income)(5) (45 ) 57 1,061 (4,478 )
Other (income) expense, net(6) (2,378 ) (8,952 ) 1,032 (11,388 )
Loss from continuing operations before income taxes $ (41,255 ) $ (73,353 ) $ (174,587 ) $ (210,052 )

(1) The costs and operating expenses exclude expenses which are separately captioned below.
(2) Includes $0.1 million and $0.2 million in employer payroll taxes for three months ended September 30, 2026 and 2025, respectively, and $1.4 million and $0.7 million for nine months ended September 30, 2026 and 2025, respectively.
(3) See Note 3, Restructuring, for composition of costs.
(4) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
(5) Represents transaction and integration costs directly related to mergers, acquisitions, and divestitures, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.
(6) Includes interest income, interest expense, gain and loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.

INVESTORS:
[email protected]

MEDIA:
[email protected]

Source: Ginkgo Bioworks Holdings, Inc.

Categories: Press Releases

View all news

Quick Links

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ginkgo Bioworks, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ginkgo Bioworks to send you the requested Investor Email Alert updates.

* Required

Email *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
SEC Filings (excluding ownership disclosures)
End of Day Stock Quote
Form 144/Ownership Disclosures
Quarterly and Annual Reports

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Ginkgo Bioworks

October 29, 2026

Download(opens in new window)PDF

Presentation and Q&A session scheduled for post-market on Thursday, November 5, 2026

BOSTON – October 29, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, beginning at 4:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available. 

To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

About Ginkgo Bioworks

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo’s in-house autonomous lab is also available as a “cloud lab” through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com , read our blog , or follow us on social media channels such as X (@Ginkgo ), Instagram (@GinkgoBioworks ), Threads (@GinkgoBioworks ), or LinkedIn .

Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news). Ginkgo uses these channels, as well as its blog (https://www.ginkgo.bio/resources) and social media accounts on X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) and LinkedIn to communicate with investors and the public about the Company and other matters and encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

Ginkgo Bioworks Contacts: 

INVESTOR CONTACT:

[email protected]    

MEDIA CONTACT:

[email protected] 

Categories: Press Releases

View all news

Quick Links

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ginkgo Bioworks, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ginkgo Bioworks to send you the requested Investor Email Alert updates.

* Required

Email *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
SEC Filings (excluding ownership disclosures)
End of Day Stock Quote
Form 144/Ownership Disclosures
Quarterly and Annual Reports

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Ginkgo Bioworks

October 8, 2026

Download(opens in new window)

BOSTON, Mass., October 8, 2026 –– Ginkgo Bioworks Holdings, Inc. (we,” “us,” “our” and “the Company”) recently discovered an unauthorized third party accessed data (“Affected Data”) from cloud environments primarily associated with the Company’s former biosecurity business. We took immediate steps to secure our systems and investigate the situation.

What actions we took

  • We launched an investigation with assistance from an independent third-party cybersecurity response team and forensic experts at a leading national forensic firm, together with outside counsel. The investigation is ongoing.
  • We implemented our cybersecurity response plan consistent with our previously established cyber incident protocols.
  • We informed the FBI of this incident and are cooperating with federal law enforcement in the investigation. 
  • We believe we have notified all of our customers whose data was included in the Affected Data and are evaluating applicable regulatory and legal notification requirements. We intend to make all required notifications based on our findings.

What we know about the affected data

At this time, we believe the Affected Data involved was primarily from legacy cloud environments. We promptly terminated the third party’s access and began mitigation measures such as rotating credentials. We have found no evidence that the third party has continued access to the affected environments and at this time found no evidence that the third party accessed environments other than the one holding the Affected Data. While some legacy systems were temporarily taken offline as a precautionary measure, there has been no interruption to our core systems, including our financial systems. This was not a ransomware or encryption event, and the Company’s operations have not been disrupted to date.

About Ginkgo Bioworks 

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo’s in-house autonomous lab is also available as a “Cloud Lab” through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements regarding the ongoing nature of the Company’s investigation, the Company’s preliminary findings regarding the scope of the incidents, the status of the affected environments, and the Company’s intentions to make all required notifications. Factors that could cause actual results to differ from those expressed in these forward-looking statements include: findings from the ongoing investigation of the incident; actions taken by the third party, including any publication of data; the potential consequences resulting from the incident or additional cybersecurity incidents; and the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 26, 2026, and other documents filed by the Company from time to time with the SEC. All forward looking statements are based on information and estimates available to us as of the date hereof. Unless required by law, the Company expressly disclaims any obligation to update publicly any forward-looking statements, whether as result of new information, future events or otherwise.

GINKGO BIOWORKS INVESTOR CONTACT:

[email protected]

GINKGO BIOWORKS MEDIA CONTACT:

[email protected]

# # #

Categories: Press Releases

View all news

Quick Links

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ginkgo Bioworks, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ginkgo Bioworks to send you the requested Investor Email Alert updates.

* Required

Email *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
SEC Filings (excluding ownership disclosures)
End of Day Stock Quote
Form 144/Ownership Disclosures
Quarterly and Annual Reports

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Ginkgo Bioworks

Prompts

Ginkgo Bioworks Holdings, Inc. (ticker DNA), listed in United States.

Company History

Date Change Detail
Aug 19, 2021 Renamed SOARING EAGLE ACQUISITION CORP. → GINKGO BIOWORKS HOLDINGS, INC.
Nov 25, 2020 Renamed Spinning Eagle Acquisition Corp. → SOARING EAGLE ACQUISITION CORP.
— Former tickers DNABW

ETFs Holding Ginkgo Bioworks Holdings, Inc.

ETF Weight in ETF Shares Market value As of
ORR short -0.13% -55,485 $ -460K Nov 18, 2026
NXTE 0.08% 4,496 $ 44.555K Jun 30, 2026
AVSC 0.03% 102,819 $ 873.962K Nov 16, 2026
DFAS 0.01% 186,243 $ 1.905M Nov 12, 2026
DXUV 0.00% 17,315 $ 177.132K Nov 12, 2026
DFSU 0.00% 4,528 $ 46.321K Nov 12, 2026
MSSM 0.00% 1,961 $ 13.354K Aug 31, 2026
DFAU 0.00% 15,637 $ 159.967K Nov 12, 2026
DCOR 0.00% 39,978 $ 408.975K Nov 12, 2026
DFAC 0.00% 54,066 $ 553.095K Nov 12, 2026
DFUS 0.00% 12,840 $ 131.353K Nov 12, 2026
AVUS 0.00% 504 $ 4,284.00 Nov 16, 2026